Nxstage Medical (NXTM) Reports In-Line Q4 EPS; Issues Light FY16 Revenue Outlook

Nxstage Medical (NASDAQ: NXTM) reported Q4 EPS of ($0.04), in-line with the analyst estimate of ($0.04). Revenue for the quarter came in at $89.8 million versus the consensus estimate of $86.83 million.

GUIDANCE:

Nxstage Medical sees Q1 2016 revenue of $87-89 million, versus the consensus of $89.3 million.

Nxstage Medical sees FY2016 revenue of $355-360 million, versus the consensus of $371.0 million.

For earnings history and earnings-related data on Nxstage Medical (NXTM) click here.

You May Also Be Interested In

• Outlook Therapeutics (OTLK) Misses Q3 EPS by 9c
• Instil Bio Inc. (TIL) Misses Q2 EPS by 21c
• Boost Run, Inc. (BRUN) Reports Q2 Revenue of $31.1M